The forecast for sold production of antisera, other immunological products, and other blood fractions in France shows a consistent upward trend from 2024 through 2028. Starting at 6.2748 billion euros in 2024, the sector is projected to grow annually, reaching 9.4818 billion euros by 2028. This represents a steady compound annual growth rate (CAGR) over the 5-year period.

The year-on-year growth rates are notable, with each subsequent year reflecting positive growth: 13% from 2024 to 2025, 11.37% from 2025 to 2026, 10.11% from 2026 to 2027, and 9.09% from 2027 to 2028. This consistent growth underscores strong market demand and innovation within the sector.

Future trends to watch for include:

Advancements in biotechnology and their impact on production efficiency and product diversity.
Regulatory changes within the EU that may affect production and distribution.
Potential shifts in global health priorities influencing demand for immunological products.